Mr. Witoshkin brings extensive experience from pharmaceutical, healthcare
and biomedical industries
FRANKLIN, Mass., Feb. 21 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (SONT.PK) announced today the appointment of Walter Witoshkin
to its board of directors.
"I am pleased to be joining the Sontra board," said Mr. Witoshkin. "I
am looking forward to working with the Sontra board and management in
further developing Sontra's intellectual property and business
opportunities."
"On behalf of the entire board, we welcome the addition of Walter
Witoshkin," said Michael Wigley, Chairman of the Board of Directors of
Sontra. "His experience with technology, medical device and public
companies will be valuable in the Company's continuing development."
Mr. Witoshkin is Chairman and Chief Executive Officer of QuantRx
Biomedical Corporation (OTCBB: QTXB). A 40-year veteran of the
pharmaceutical, healthcare and biomedical industries, Mr. Witoshkin joined
QuantRx in 2005. He has held senior executive positions at leading
healthcare product and pharmaceutical companies, most recently SmithKline
Beecham, now Glaxo SmithKline, where he was Vice President of Business
Development and Chief Financial Officer. In 1989, Mr. Witoshkin established
Menley & James Laboratories, Inc., after purchasing 32 SmithKline Beecham
over-the-counter pharmaceutical and toiletry product brands. Menley & James
had its initial public offering in 1992. He earlier held several senior
finance positions at American Cyanamid, which became American Home and then
Wyeth. Mr. Witoshkin joined QuantRx from Trident Group LLC, global
operational consultants to the pharmaceutical and related healthcare
industries. As a founding partner of Trident Group, Mr. Witoshkin
specialized in alternative sourcing for manufacturing and the acquisition
of technologies and products.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation, a technology leader in transdermal science,
is developing a non-invasive, continuous transdermal glucose monitor
("CTGM") for use in the Diabetes and Intensive Care Markets. In addition,
the Company owns the FDA approved SonoPrep(R) ultrasound-mediated skin
permeation technology, presently used with topical lidocaine to achieve
rapid (within five minutes) skin anesthesia. The Company is using SonoPrep
and other technical competencies in transdermal drug formulation, delivery
systems and biosensors to develop a new paradigm in transdermal drug
delivery and diagnosis.
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks
or registered trademarks of their respective owners.
Investor Relations Contacts:
Harry G. Mitchell, Interim CEO
508-530-0311
hmitchell@sontra.com
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com
CONTACT:
Investor Relations, Harry G. Mitchell,
Interim CEO of Sontra Medical Corporation, +1-508-530-0311, or
hmitchell@sontra.com
|
